Journal Logo

Institutional members access full text with Ovid®

Cellular Strategies for Enhancement of Fracture Repair

Patterson, Thomas E., PhD; Kumagai, Ken, MD, PhD; Griffith, Linda, PhD; Muschler, George F., MD

doi: 10.2106/JBJS.G.01572
Symposium Articles
Buy

Tissue engineering seeks to translate scientific knowledge into tangible products to advance the repair, replacement, or regeneration of organs and tissues. Current tissue engineering strategies have progressed recently from a historical approach that is based primarily on biomaterials to a cell and tissue-based approach that includes understanding of cell-sourcing and bioactive stimuli. New options include methods for harvest and transplantation of tissue-forming cells, bioactive matrix materials that act as tissue scaffolds, and delivery of bioactive molecules within scaffolds. These strategies are already benefiting patients, and they place increasing demands on orthopaedic surgeons to have a solid foundation in the contemporary concepts and principles of cell-based tissue engineering.

Essentially all orthopaedic tissue engineering strategies can be distilled to a strategy or combination of strategies that seek to increase the number or relative performance of bone-forming cells. The global term connective tissue progenitors has been used to define the heterogeneous populations of stem and progenitor cells that are found in native tissue and that are capable of differentiating into one or more connective tissue phenotypes. These stem or progenitor populations are found in various tissue sources, with varying degrees of ability to differentiate along connective tissue lineages. Available cell-based strategies include targeting local cells with use of scaffolds or bioactive factors, or transplantation of autogenous connective tissue progenitor cells derived from bone marrow or other tissues, with or without processing to change their concentration or prevalence. The future may include means of homing circulating connective tissue progenitor cells with use of intrinsic chemokine systems, or modifying the biological performance of connective tissue progenitor cells by means of genetic modifications.

Corresponding author: George F. Muschler, MD Departments of Orthopaedic Surgery and Biomedical Engineering (ND-20), Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195. E-mail address: muschlg@ccf.org

Copyright © 2008 by The Journal of Bone and Joint Surgery, Incorporated
You currently do not have access to this article

To access this article: